Uptake In Vaccinations Shows Prudent Investment Opportunity In Biotech Industry

Over the past few decades, the rampant growth and expansion in the vaccination industry have yielded impressive results. From Polio vaccine in 1954, the MMR combination vaccine in 1971, the first recombinant vaccines for hepatitis-B in the 1980s, a vaccine for the cancer-causing Human Papillomavirus (HPV) in 2006, an Ebola vaccine in 2019, and now the recent vaccine development efforts for SARS-CoV-2, each milestone marks considerable annual growth in the pharmaceutical and biotech industries. Now, new technologies and the clinical and commercial success of vaccines has left them poised as a prudent investment opportunity.

With ever-evolving diseases and new threats constantly challenging the status quo of global health and well-being, the demand for vaccines has increased immensely, further enhancing the overall opportunity that investing in vaccine developers offers investors. The COVID-19 pandemic outlines this perfectly, with Pfizer, Novavax, Moderna, and several other companies share prices showing tremendous upside following their vaccine development efforts.

Now, there is an emphasis on greater foresight and planning to combat the next global pandemic, with the biotechnology industry positioning itself at the forefront of this challenge. Driven by new scientific understandings and technical advancements, biotech companies are playing a vital role in the development of present and future vaccination campaigns along with their pursuit of novel infectious disease research since the start of Covid-19.

Also, with heightened interest in public safety and better governance of public policies, biotech companies are leading the way in shaping and forming forward-thinking expectations of how the world will tackle future events. This also provides the opportunity to pursue more modern therapeutics and novel areas of research. Investments in these forward-thinking companies are therefore essential to combat potential delays in future events, whilst also providing a unique opportunity to help reset an industry in much need of reform.

BioVaxys, a clinical-stage biopharma company, is currently developing a vaccine for SARS-CoV-2 and an anticancer vaccine platform against late stage ovarian cancer and a range of other cancers, which uses haptenized tumor cell technology for treatment. The global cancer therapeutics market is estimated to reach $172.6 billion by 2022, leading to a potential upside that is well worth the risk. With this in mind, biotechnology companies such as BioVaxys can provide a lucrative, long-term investment vehicle with room for exponential market growth and success.

COVID-19 is not the first pandemic the world has encountered but further exposed our weaknesses and exploited how unprepared the world was. Now, with market-leading research and key breakthroughs made annually, combined with the need for greater control and foresight over global events, biotechnologies should remain a key strategic consideration for your investment portfolio.

For more info check out the BioVaxys’ official website: https://biovaxys.com/

This article does not necessarily reflect the opinions of the editors or the management of EconoTimes